A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
NCT01215968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2014-10-07
Summary
The primary purpose of this Study is to help answer the following research question(s).
* How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes?
* How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)?
* Is LY2189265 safe and are any side effects associated with it?
The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5.
Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- BIOLOGICAL
-
LY2189265
1.5 mg administered subcutaneously
- DRUG
-
Administered subcutaneously
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2011-07-31
- Completion
- 2011-07-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01558271 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
NCT06869018 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
NCT04586907 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
NCT05478525 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2922470 in Healthy Participants and Participants With Diabetes
NCT01746017 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
NCT04591626 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3185643 and rGlucagon in Healthy Participants
NCT02951780 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)
NCT00790556 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
NCT07073170 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
NCT04809220 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes
NCT01615978 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03315780 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes
NCT02686281 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
NCT04465877 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes
NCT06567041 ·Status: COMPLETED ·Phase: PHASE1
-
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
NCT01293669 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
NCT00495469 ·Status: COMPLETED ·Phase: PHASE2
-
Study In People With Type 2 Diabetes
NCT00196989 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01468181 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
NCT01013766 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT05327595 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
NCT00846391 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
NCT00382239 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00762684 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
NCT02589639 ·Status: COMPLETED ·Phase: PHASE4